-
1
-
-
33746225229
-
Doripenem
-
Anderson, D. L. 2006. Doripenem. Drugs Today 42:399-404.
-
(2006)
Drugs Today
, vol.42
, pp. 399-404
-
-
Anderson, D.L.1
-
2
-
-
24144496190
-
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem
-
Bhavnani, S. M., J. P. Hammel, B. B. Cirincione, M. A. Wikler, and P. G. Ambrose. 2005. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob. Agents Chemother. 49:3944-3947.
-
(2005)
Antimicrob. Agents Chemother
, vol.49
, pp. 3944-3947
-
-
Bhavnani, S.M.1
Hammel, J.P.2
Cirincione, B.B.3
Wikler, M.A.4
Ambrose, P.G.5
-
4
-
-
0030049979
-
Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin
-
Dreetz, M., J. Hamacher, and J. Eller. 1996. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob. Agents Chemother. 40:105-109.
-
(1996)
Antimicrob. Agents Chemother
, vol.40
, pp. 105-109
-
-
Dreetz, M.1
Hamacher, J.2
Eller, J.3
-
5
-
-
2142760947
-
Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug.' Nat. Rev. Microbiol
-
Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat. Rev. Microbiol. 2:289-300.
-
(2004)
, vol.2
, pp. 289-300
-
-
Drusano, G.L.1
-
6
-
-
28644447594
-
Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003)
-
Fritsche, T. R., M. G. Stilwell, and R. N. Jones. 2005. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin. Microbiol. Infect. 11:974-984.
-
(2005)
Clin. Microbiol. Infect
, vol.11
, pp. 974-984
-
-
Fritsche, T.R.1
Stilwell, M.G.2
Jones, R.N.3
-
7
-
-
1642420265
-
In vitro antimicrobial activity of doripenem, a new carbapenem
-
Ge, Y., M. A. Wikler, D. F. Sahm, J. A. Karlowsky, and R. S. Blosser-Middleton. 2004. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob. Agents Chemother. 48:1384-1396.
-
(2004)
Antimicrob. Agents Chemother
, vol.48
, pp. 1384-1396
-
-
Ge, Y.1
Wikler, M.A.2
Sahm, D.F.3
Karlowsky, J.A.4
Blosser-Middleton, R.S.5
-
9
-
-
30844454044
-
Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals
-
Hori, T., M. Nakano, Y. Kimura, and F. Murakami. 2006. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo 20:91-96.
-
(2006)
In Vivo
, vol.20
, pp. 91-96
-
-
Hori, T.1
Nakano, M.2
Kimura, Y.3
Murakami, F.4
-
10
-
-
3342910269
-
Activities of doripenem (S-4661) against drug-resistant clinical pathogens
-
Jones, R. N., H. K. Huynh, and D. J. Biedenbach. 2004. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob. Agents Chemother. 48:3136-3140.
-
(2004)
Antimicrob. Agents Chemother
, vol.48
, pp. 3136-3140
-
-
Jones, R.N.1
Huynh, H.K.2
Biedenbach, D.J.3
-
11
-
-
18844415653
-
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli and various β-lactamase resistance mechanisms
-
Jones, R. N., H. S. Sader, and T. R. Fritsche. 2005. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli and various β-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis. 52:71-74.
-
(2005)
Diagn. Microbiol. Infect. Dis
, vol.52
, pp. 71-74
-
-
Jones, R.N.1
Sader, H.S.2
Fritsche, T.R.3
-
12
-
-
34548177850
-
Uniformly enhanced activity of doripenem compared to other carbapenems (imipenem, meropenem) when testing P. aeruginosa isolates: Results from three continents
-
Abstract
-
Jones, R. N., M. G. Stillwell, H. S. Sader, and T. R. Fritsche. 2006. Uniformly enhanced activity of doripenem compared to other carbapenems (imipenem, meropenem) when testing P. aeruginosa isolates: results from three continents. Int. J. Infect. Dis. 10(Suppl. 1):S127-S128. (Abstract.)
-
(2006)
Int. J. Infect. Dis
, vol.10
, Issue.SUPPL. 1
-
-
Jones, R.N.1
Stillwell, M.G.2
Sader, H.S.3
Fritsche, T.R.4
-
13
-
-
0030977235
-
Pharmacokinetics of meropenem in animals, healthy volunteers, and patients
-
Moon, Y. S. K., K. C. Chung, and M. A. Gill. 1997. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin. Infect. Dis. 24(Suppl. 2):S249-S255.
-
(1997)
Clin. Infect. Dis
, vol.24
, Issue.SUPPL. 2
-
-
Moon, Y.S.K.1
Chung, K.C.2
Gill, M.A.3
-
14
-
-
0033804883
-
Comparative pharmacokinetics of the carbapenems. Clinical implications
-
Mouton, J. W., D. J. Touw, A. M. Horrevorts, and A. A. Vinks. 2000. Comparative pharmacokinetics of the carbapenems. Clinical implications. Clin. Pharmacokinet. 39:185-201.
-
(2000)
Clin. Pharmacokinet
, vol.39
, pp. 185-201
-
-
Mouton, J.W.1
Touw, D.J.2
Horrevorts, A.M.3
Vinks, A.A.4
-
15
-
-
1642502313
-
Comparative activities of doripenem versus isolates, mutants, and transconjugates of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases
-
Mushtaq, S., Y. Ge, and D. M. Livermore. 2004. Comparative activities of doripenem versus isolates, mutants, and transconjugates of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob. Agents Chemother. 48:1313-1319.
-
(2004)
Antimicrob. Agents Chemother
, vol.48
, pp. 1313-1319
-
-
Mushtaq, S.1
Ge, Y.2
Livermore, D.M.3
-
16
-
-
0021685387
-
Disposition of radiolabeled imipenem and cilastatin in normal human volunteers
-
Norrby, S. R., J. D. Rogers, F. Ferber, K. H. Jones, A. G. Zacchei, and L. L. Weidner. 1984. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob. Agents Chemother. 26:707-714.
-
(1984)
Antimicrob. Agents Chemother
, vol.26
, pp. 707-714
-
-
Norrby, S.R.1
Rogers, J.D.2
Ferber, F.3
Jones, K.H.4
Zacchei, A.G.5
Weidner, L.L.6
-
17
-
-
33744950954
-
Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa. The high potency of a new carbapenem doripenem
-
Sakyo, S., H. Tomita, K. Tanimoto, S. Fujimoto, and Y. Ike. 2006. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa. The high potency of a new carbapenem doripenem. J. Antibiot. 59:220-228.
-
(2006)
J. Antibiot
, vol.59
, pp. 220-228
-
-
Sakyo, S.1
Tomita, H.2
Tanimoto, K.3
Fujimoto, S.4
Ike, Y.5
-
18
-
-
2442631499
-
14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey, and man
-
14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey, and man. Xenobiotica 34:379-389.
-
(2004)
Xenobiotica
, vol.34
, pp. 379-389
-
-
Wong, B.K.1
Sahly, Y.2
Mistry, G.3
Waldman, S.4
Musson, D.5
Majumdar, A.6
Xu, X.7
Yu, S.8
Lin, J.H.9
Singh, R.10
Holland, S.11
-
19
-
-
33846798522
-
Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem
-
Yamano, Y., T. Nishikawa, T. Fujimura, T. Yutsudou, M. Tsuji, and H. Miwa. 2006. Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem. J. Antibiot. 59:791-796.
-
(2006)
J. Antibiot
, vol.59
, pp. 791-796
-
-
Yamano, Y.1
Nishikawa, T.2
Fujimura, T.3
Yutsudou, T.4
Tsuji, M.5
Miwa, H.6
|